Despite plans to broaden its business beyond obesity treatments, the Danish group’s forecasts are modest, indicating limited growth prospects outside its weight‑loss medication portfolio.
The Danish pharmaceutical company Novo Nordisk posted a strong Q2, achieving €10.5 bn in sales and €4.465 bn in adjusted operating profit, up 2% and 8% from the previous year.
Novo Nordisk A/S’s largest shareholder is backing a new Italian startup accelerator as part of an initiative to support early-stage life science companies across Europe beyond Denmark’s borders.